{'fraction_non_alphanumeric': 0.03787878787878788, 'fraction_numerical': 0.020833333333333332, 'mean_word_length': 6.779411764705882, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy

Duchenne and Becker muscular dystrophies (DBMD) are allelic disorders caused by mutations in dystrophin. Adults with DBMD develop life‐threatening cardiomyopathy. Inhibition of phosphodiesterase 5 (PDE5) improves cardiac function in mouse models of DBMD. To determine whether the PDE5‐inhibitor sildenafil benefits human dystrophinopathy, we conducted a randomized, double‐blind, placebo‐controlled trial (ClinicalTrials.gov, number NCT01168908).